Home » Stocks » XBIT

XBiotech Inc. (XBIT)

Stock Price: $17.11 USD -0.01 (-0.06%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 513.02M
Revenue (ttm) 36.17M
Net Income (ttm) -13.78M
Shares Out 29.42M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $17.11
Previous Close $17.12
Change ($) -0.01
Change (%) -0.06%
Day's Open 17.12
Day's Range 16.96 - 17.39
Day's Volume 32,571
52-Week Range 12.76 - 21.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Phas...

3 weeks ago - Benzinga

XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer

3 weeks ago - GlobeNewsWire

These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.

Other stocks mentioned: APPS, CYH, NARI, NVAX, RVP, TBBK, VERI ...
2 months ago - Investopedia

With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectious Strain R...

3 months ago - GlobeNewsWire

Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Alb...

3 months ago - GlobeNewsWire

These are the small cap stocks with the best value, fastest growth, and most momentum for January 2021.

Other stocks mentioned: ATEN, EYE, FCEL, NVAX, SWBI, UIS, VHC ...
4 months ago - Investopedia

These are the small cap stocks with the best value, fastest growth, and most momentum for December 2020.

Other stocks mentioned: CTRN, LPX, NLS, NVAX, UCTT, UIS, VHC ...
5 months ago - Investopedia

XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing safer/more effective therapeutics through human-based monoclonal antibodies. XBiotech's pipeline consists of 4 candidate...

5 months ago - Seeking Alpha

Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential

5 months ago - GlobeNewsWire

These are the small cap stocks with the best value, fastest growth, and most momentum for November 2020.

Other stocks mentioned: BIG, CODX, NVAX, TGH, TTMI, UIS, VHC ...
6 months ago - Investopedia

As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Cataly...

Other stocks mentioned: CPRX, PRDO, SBR, VNDA
6 months ago - GuruFocus

These are the small cap stocks with the best value, fastest growth, and most momentum for October 2020.

Other stocks mentioned: BIG, CODX, NVAX, TGH, TTMI, UIS, VHC ...
7 months ago - Investopedia

With the Arrival of Flu Season, Development of a Breakthrough Therapeutic for Treating Influenza and COVID-19 Co-Infections is Urgently Needed With the Arrival of Flu Season, Development of a Breakthrou...

7 months ago - GlobeNewsWire

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: GMAB, INVA, MRSN, NVAX, REGN, TECH, VNDA
8 months ago - Investopedia

These are the small cap stocks with the best value, fastest growth, and most momentum for September.

Other stocks mentioned: CODX, ICHR, NVAX, PRTS, TGH, TTM, UIS ...
8 months ago - Investopedia

FDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients

8 months ago - GlobeNewsWire

XBiotech Inc. (NASDAQ: XBIT) shares made a handy gain on Monday after the company said that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2.

8 months ago - 24/7 Wall Street

The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood

8 months ago - GlobeNewsWire

Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.

Other stocks mentioned: ALXN, CRSP, EDIT, VRTX
9 months ago - InvestorPlace

XBiotech: Well Funded, Working On The Next Bermekimab, And Undervalued

9 months ago - Seeking Alpha

After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021 After Sale of its Previous Anti-IL-1a True H...

9 months ago - GlobeNewsWire

When Wall Street ignores micro-cap stocks, it creates deep value opportunities, if a company is able to turn things around against fortune.

Other stocks mentioned: ARLO, ITRN, LQDA, RADA, SWIR, VERI
9 months ago - InvestorPlace

Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy Antibody Therapy Targeting Interleukin-1a significa...

10 months ago - GlobeNewsWire

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: GMAB, IBB, INVA, NVAX, TRIL, VNDA, VRTX
11 months ago - Investopedia

Donors with Potent Natural Immunity Against the Virus are Identified as the Starting Point for XBiotech’s Drug Development Program to Treat COVID-19

1 year ago - GlobeNewsWire

These are the small cap stocks with the best value, fastest growth, and most momentum for May.

Other stocks mentioned: KOD, TPH
1 year ago - Investopedia

These exciting stocks to buy for aggressive investors might be small, but they have massive growth potential when the pandemic clears up. The post 7 Top Stocks to Buy for Aggressive Investors appeared...

Other stocks mentioned: DRD, ENPH, IFMK, NH, OESX
1 year ago - InvestorPlace

New antibody to block IL-1⍺ scheduled to enter clinical trials as next generation anti-inflammatory therapy in 2021 New antibody to block IL-1⍺ scheduled to enter clinical trials as next generation anti...

1 year ago - GlobeNewsWire

AUSTIN, Texas, April 03, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) and BioBridge Global today announced their collaboration to participate in a U.S. Food and Drug Administration (FDA) inve...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., N...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- This press release corrects a prior version published on February 13, 2020 and is updated to revise the preliminary proration factor.  The corrected pr...

1 year ago - GlobeNewsWire

The company's offer to buy back shares was overtendered, resulting in a prorated deal.

1 year ago - The Motley Fool

AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00 p...

1 year ago - GlobeNewsWire

XBiotech Is Trading Below Its $30 Offer Price For Good Reason, But It Still Could Rise

1 year ago - Seeking Alpha

The company is offering to buy back shares from investors at a big premium.

1 year ago - The Motley Fool

AUSTIN, Texas, Jan. 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) announced today that it commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of i...

1 year ago - GlobeNewsWire

Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Anti...

1 year ago - GlobeNewsWire

XBiotech Move To Out-Licence Next Generation Antibody Brings In Substantial Cash For Pipeline Expansion

1 year ago - Seeking Alpha

AUSTIN, Texas, Dec. 17, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to...

1 year ago - GlobeNewsWire

XBiotech announced a massive deal with Johnson & Johnson subsidiary Janssen, which is thrusting the overlooked biopharma onto the radars of investors.

1 year ago - The Motley Fool

Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some.

Other stocks mentioned: ARQL, THO
1 year ago - 24/7 Wall Street

XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen XBiotech wi...

1 year ago - GlobeNewsWire

Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS

1 year ago - GlobeNewsWire

AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate its IL...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Oct. 23, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical s...

1 year ago - GlobeNewsWire

Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a Devastating Disease with Currently No Approved Therapies Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a Devastati...

1 year ago - GlobeNewsWire

Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Saturday, October 12, 2019 Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Saturday, Octob...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the u...

1 year ago - GlobeNewsWire

Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?

Other stocks mentioned: AGN, CRSP, REGN, VRTX
2 years ago - InvestorPlace

About XBIT

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical tri... [Read more...]

Industry
Biotechnology
IPO Date
Apr 15, 2015
CEO
John Simard
Employees
91
Stock Exchange
NASDAQ
Ticker Symbol
XBIT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for XBiotech is 18.00, which is an increase of 5.20% from the latest price.

Price Target
$18.00
(5.20% upside)